Cukrzyca - postep w badanich Dodaj do ulubionych

  • 04.03.04, 13:57
    Contact: Michael C. Purdy
    (314) 286-0122
    purdym@wustl.edu



    Printable Version



    Embryonic Pig Cell Transplants Halt Rat Diabetes: Procedure Requires No
    Immune Suppression Drugs


    St. Louis, Feb. 25, 2004 — An experimental cross-species transplant to treat
    diabetes has passed an early test in rats with better-than-expected results,
    suggesting the innovative approach might halt type 1 diabetes while greatly
    reducing the risk of rejection.

    Scientists at Washington University School of Medicine in St. Louis set up
    control and experimental groups of rats with diabetes. The experimental group
    received embryonic pig pancreas cell transplants and antirejection drugs to
    prevent the rats’ immune systems from destroying the transplants. The control
    group received only the transplants and no immune suppression drugs. To the
    researchers’ surprise, the control group’s transplants grew unmolested by the
    immune system, halting the rats’ diabetes and changing the focus of the study
    to transplanting without the need for immune suppression.

    “Every once in a while you get lucky, and now we have the possibility of
    transplanting these pig cells and not having to worry about rejection,” says
    Marc R. Hammerman, M.D., the Chromalloy Professor of Renal Diseases in
    medicine and leader of the study.

    The results appear online and will be published in the April issue of The
    American Journal of Physiology-Endocrinology and Metabolism.

    Hammerman, an endocrinologist and director of the Renal Division, is a leader
    in the emerging field of organogenesis, which is focused on growing organs
    from stem cells and other embryonic cell clusters known as organ primordia.
    Unlike stem cells, primordia cannot develop into any cell type — they are
    locked into becoming a particular cell type or one of a particular set of
    cell types that make up an organ.

    In multiple groups of diabetic rats that were unable to produce their own rat
    insulin, Hammerman and Sharon Rogers, research instructor in medicine,
    transplanted pig pancreas primordia into the omentum, a membrane that
    envelops the intestines and other digestive organs. Within two weeks, the
    primordia engrafted and began producing pig insulin.

    The pig insulin replaced the missing rat insulin, returning the rats’ blood
    glucose to normal levels, an effect that continued for the rest of their
    lives. Failure to gain weight, another characteristic symptom of diabetes,
    was also reversed following the transplants.

    In a final group of transplant recipients, Rogers, Hammerman, Feng Chen,
    Ph.D., assistant professor of medicine, and Mike Talcott, D.V.M., director of
    veterinary surgical services, showed that pig insulin-producing cells were
    present in the omentum and had caused a buildup of fat, a change previously
    linked to successful engraftment of pancreatic tissue.

    Hammerman had theorized for years that implanting primordia obtained very
    soon after organ formation and coaxing the cells into growing into fully
    functioning organs inside a transplant recipient might reduce immune system
    rejection. However, he admits he is stunned by the new success.

    “Conditions that are permissive for transplantation from one species to
    another frequently don’t translate to transplants into another species,”
    Hammerman says. “But this dramatic elimination of the need for immune
    suppression is quite unusual; there’s not a lot of precedent in the
    literature for it. So it’s possible that it may also apply in other cross-
    species transplants and maybe even in pig-to-human transplants.”

    Diabetes in humans is sometimes treated by transplanting human insulin-
    producing pancreas cells known as the islets of Langerhans. According to
    Hammerman, using embryonic pig cells as the transplant source instead of
    human islets circumvents three major difficulties.

    “First, there aren’t nearly enough human pancreas organs to go around,”
    Hammerman says. “Since pig insulin works fine in humans, if pigs could be
    used as donors the shortage would be alleviated.”

    Second, islets can only be extracted from the pancreas by mincing the organ
    and exposing it to enzymes that break down connective tissue.

    “This damages islets,” Hammerman says. “So not all of the transplanted islets
    engraft, and many that do engraft die after a period of time.”

    Third, islets are composed of mature cells unable to respond to increased
    need for their services by dividing and producing more cells. In contrast,
    embryonic pancreas cells divide readily in response to such needs, resulting
    in a potentially expandable source of insulin.

    For reasons not yet understood, the transplanted pancreas cells did not
    develop an additional digestive function normally associated with the
    pancreas.

    “That was another remarkably lucky break,” Hammerman notes, “because only the
    endocrine cells are required to treat diabetes. The digestive cells would
    have only caused problems.”

    If elimination or reduction of immune rejection transfers to pig-to-human
    transplants, the technique will defeat or greatly diminish a final formidable
    obstacle to treating diabetes with transplants.

    “Immunosuppressing a patient introduces a whole new set of dangers and side
    effects,” says Hammerman. “Patients with type 1 diabetes have to ask
    themselves, would I rather take insulin, or would I rather take all these
    immunosuppressive drugs? It’s not the greatest choice in the world.”

    The next phase of research will involve pig-to-primate transplants. If those
    are successful, then pig-to-human transplant trials can be considered.

    Hammerman also is studying the use of kidney primordia from embryonic pigs to
    grow new kidneys inside recipients as a treatment for end-stage kidney
    failure.

    ###




Wysyłaj powiadomienia o nowych wpisach na forum na e-mail:

Aby uprościć zarządzanie powiadomieniami zaloguj się lub zarejestruj się.

lub anuluj

Zaloguj się

Nie pamiętasz hasła lub loginu ?

Nie masz jeszcze konta? Zarejestruj się

Nakarm Pajacyka
Agora S.A. - wydawca portalu Gazeta.pl nie ponosi odpowiedzialności za treść wypowiedzi zamieszczanych przez użytkowników Forum. Osoby zamieszczające wypowiedzi naruszające prawo lub prawem chronione dobra osób trzecich mogą ponieść z tego tytułu odpowiedzialność karną lub cywilną. Regulamin.